Clinical Trial Update: Clinical Study to Evaluate the Efficacy and Safety of GS1-144 Tablets in the Treatment of Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the efficacy and safety of GS1-144 tablets for vasomotor symptoms in Chinese postmenopausal women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vasomotor Syndrome

Drugs mentioned

• GS1-144 tablets (GS1-144)

Snippet

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Conditions: Vasomotor Syndrome | Phase 2 | Status: COMPLETED